• The Ensign Group, Inc. has declared a quarterly cash dividend of $0.06 per share of Ensign common stock.
• The dividend will be payable on or before October 31, 2024, to shareholders of record as of September 30, 2024.
• Ensign is a group of companies that invest in and provide skilled nursing and senior living services, physical, occupational, and speech therapies, other rehabilitative and healthcare services, and real estate.
SAN JUAN CAPISTRANO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.06 per share of Ensign common stock, payable on or before October 31, 2024, to shareholders of record as of September 30, 2024.
Ensign has been a dividend-paying company since 2002.
About Ensign™
The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 323 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.
Contact Information
The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$151.00 |
| Daily Change: | -1.03 -0.68 |
| Daily Volume: | 259,142 |
| Market Cap: | US$8.620B |
September 03, 2024 September 03, 2024 July 25, 2024 June 04, 2024 June 04, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
